PARABDRUGS · PARABDRUGS
Every PARABDRUGS result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
3results judged
0read right
0read wrong
0flat / no call
3unread
67%beat the market
+19.6%avg vs market, 10d
2.7%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| unread | 3 | 0 | 0 | 0 | — | +19.6% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
3 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 8 Dec Q2FY21 | — | unread | +8.0% | +56.0% | +55.2% | -2% | no figures |
|
› |
| 5 Nov Q1FY21 | — | unread | +0.0% | +2.1% | -5.1% | -2% | no figures |
|
› |
| 18 Jul Q4FY20 | — | unread | +0.0% | +8.7% | +8.8% | +28% | no figures |
|
› |